FSI et al. invest €40m in Cerenis Therapeutics

The French government-backed FSI contributed €20m to the round. The remainder was provided by Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.

Founded in 2005, Cerenis is a biopharmaceutical company specializing in the research and development of novel therapies based on the metabolism of "good" cholesterol, in order to treat cardiovascular and other metabolic diseases.

This third round of financing will be used to advance Cerenis's lead solution for the treatment of cardiovascular diseases. It brings the total capital raised to date by the company to €107m.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Grégoire Gille on +44 20 7484 9824 or gregoire.gille@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Benelux
• UK / Ireland
• Nordics
• Southern Europe
• DACH
• CEE
• Early-stage
• Healthcare
• Sofinnova
• France